# Unicycive Therapeutics, Inc.: financial statements, quarterly

UNCY · Nasdaq · CIK 1766140 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/uncy.md) · [Financials](/companies/uncy/financials.md) · [Filings](/companies/uncy/filings.md) · [Insiders](/companies/uncy/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/uncy/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0 d](/filings/0001213900-24-097118.md) | [0.0 d](/filings/0001213900-25-025828.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [3.4](/filings/0001213900-24-097118.md) | [4.2 d](/filings/0001213900-25-025828.md) | [6.8](/filings/0001213900-25-042943.md) | [4.9](/filings/0001213900-25-076007.md) | [3.0](/filings/0001213900-25-108600.md) | [5.3 d](/filings/0001213900-26-035903.md) | [2.2](/filings/0001213900-26-054708.md) | [1.8](/filings/0001213900-26-088013.md) | [3.0](/filings/0001213900-25-108600.md) | [2.3 d](/filings/0001213900-26-035903.md) | [1.6](/filings/0001213900-26-054708.md) | [2.8](/filings/0001213900-26-088013.md) |
| Selling, general and administrative | $m | [0.5](/filings/0001213900-23-086979.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(5.9)](/filings/0001213900-24-097118.md) | [(6.3) d](/filings/0001213900-25-025828.md) | [(9.2)](/filings/0001213900-25-042943.md) | [(7.4)](/filings/0001213900-25-076007.md) | [(6.3)](/filings/0001213900-25-108600.md) | [(9.3) d](/filings/0001213900-26-035903.md) | [(8.0)](/filings/0001213900-26-054708.md) | [(7.0)](/filings/0001213900-26-088013.md) | [(7.3)](/filings/0001213900-25-108600.md) | [(7.2) d](/filings/0001213900-26-035903.md) | [(8.4)](/filings/0001213900-26-054708.md) | [(10.1)](/filings/0001213900-26-088013.md) |
| Interest expense | $m | [0.0](/filings/0001213900-23-086979.md) | [0.0 d](/filings/0001213900-24-027202.md) | [0.0](/filings/0001213900-24-042298.md) | [0.0](/filings/0001213900-25-076007.md) | [0.0](/filings/0001213900-25-108600.md) | [0.0 d](/filings/0001213900-26-035903.md) | [0.0](/filings/0001213900-26-054708.md) | [0.0](/filings/0001213900-26-088013.md) | [0.0](/filings/0001213900-25-108600.md) | [0.0 d](/filings/0001213900-26-035903.md) | not reported | not reported |
| Net income | $m | [(4.3)](/filings/0001213900-24-097118.md) | [(7.8) d](/filings/0001213900-25-025828.md) | [(21.0)](/filings/0001213900-25-108600.md) | [9.9](/filings/0001213900-25-108600.md) | [(4.1)](/filings/0001213900-25-108600.md) | [(21.5) d](/filings/0001213900-26-035903.md) | [0.6](/filings/0001213900-26-088013.md) | [(6.4)](/filings/0001213900-26-088013.md) | [(6.0)](/filings/0001213900-25-108600.md) | [(14.7) d](/filings/0001213900-26-035903.md) | [(12.8)](/filings/0001213900-26-088013.md) | [(1.7)](/filings/0001213900-26-088013.md) |
| Diluted EPS | $ per share | [(0.13)](/filings/0001213900-24-097118.md) | not reported | [(0.61)](/filings/0001213900-25-042943.md) | [(1.50)](/filings/0001213900-25-076007.md) | [(0.46)](/filings/0001213900-25-108600.md) | not reported | [(0.50)](/filings/0001213900-26-054708.md) | [(0.52)](/filings/0001213900-26-088013.md) | [(0.33)](/filings/0001213900-25-108600.md) | not reported | [(0.54)](/filings/0001213900-26-054708.md) | [(0.06)](/filings/0001213900-26-088013.md) |
| Basic EPS | $ per share | [(0.13)](/filings/0001213900-24-097118.md) | not reported | [(0.61)](/filings/0001213900-25-042943.md) | [0.80](/filings/0001213900-25-076007.md) | [(0.46)](/filings/0001213900-25-108600.md) | not reported | [0.04](/filings/0001213900-26-054708.md) | [(0.52)](/filings/0001213900-26-088013.md) | [(0.33)](/filings/0001213900-25-108600.md) | not reported | [(0.54)](/filings/0001213900-26-054708.md) | [(0.06)](/filings/0001213900-26-088013.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [14.3](/filings/0001213900-23-086979.md) | [9.7](/filings/0001213900-25-025828.md) | not reported | not reported | not reported | [26.1](/filings/0001213900-26-035903.md) | [19.8](/filings/0001213900-25-042943.md) | [22.3](/filings/0001213900-25-076007.md) | [42.7](/filings/0001213900-25-108600.md) | [29.2](/filings/0001213900-26-088013.md) | [37.4](/filings/0001213900-26-054708.md) | [44.2](/filings/0001213900-26-088013.md) |
| Current assets | $m | [18.6](/filings/0001213900-23-086979.md) | [13.4](/filings/0001213900-25-025828.md) | [51.7](/filings/0001213900-24-042298.md) | [44.1](/filings/0001213900-24-068565.md) | [37.7](/filings/0001213900-24-097118.md) | [30.9](/filings/0001213900-26-035903.md) | [27.3](/filings/0001213900-25-042943.md) | [29.5](/filings/0001213900-25-076007.md) | [50.3](/filings/0001213900-25-108600.md) | [49.0](/filings/0001213900-26-088013.md) | [63.5](/filings/0001213900-26-054708.md) | [71.3](/filings/0001213900-26-088013.md) |
| Total assets | $m | [19.4](/filings/0001213900-23-086979.md) | [14.2](/filings/0001213900-25-025828.md) | [52.4](/filings/0001213900-24-042298.md) | [44.7](/filings/0001213900-24-068565.md) | [38.6](/filings/0001213900-24-097118.md) | [31.7](/filings/0001213900-26-035903.md) | [27.9](/filings/0001213900-25-042943.md) | [30.0](/filings/0001213900-25-076007.md) | [50.6](/filings/0001213900-25-108600.md) | [49.1](/filings/0001213900-26-088013.md) | [64.4](/filings/0001213900-26-054708.md) | [72.0](/filings/0001213900-26-088013.md) |
| Current liabilities | $m | [15.5](/filings/0001213900-23-086979.md) | [17.5](/filings/0001213900-25-025828.md) | [30.3](/filings/0001213900-24-042298.md) | [13.1](/filings/0001213900-24-068565.md) | [10.5](/filings/0001213900-24-097118.md) | [24.1](/filings/0001213900-26-035903.md) | [16.7](/filings/0001213900-25-042943.md) | [13.6](/filings/0001213900-25-076007.md) | [13.1](/filings/0001213900-25-108600.md) | [18.9](/filings/0001213900-26-088013.md) | [26.5](/filings/0001213900-26-054708.md) | [18.7](/filings/0001213900-26-088013.md) |
| Total liabilities | $m | [16.0](/filings/0001213900-23-086979.md) | [18.0](/filings/0001213900-25-025828.md) | [30.7](/filings/0001213900-24-042298.md) | [13.4](/filings/0001213900-24-068565.md) | [10.7](/filings/0001213900-24-097118.md) | [24.2](/filings/0001213900-26-035903.md) | [16.7](/filings/0001213900-25-042943.md) | [13.6](/filings/0001213900-25-076007.md) | [13.1](/filings/0001213900-25-108600.md) | [18.9](/filings/0001213900-26-088013.md) | [26.7](/filings/0001213900-26-054708.md) | [18.8](/filings/0001213900-26-088013.md) |
| Shareholders' equity | $m | [3.4](/filings/0001213900-24-097118.md) | [(3.8)](/filings/0001213900-26-035903.md) | [(24.5)](/filings/0001213900-25-108600.md) | [(14.8)](/filings/0001213900-25-108600.md) | [(27.9)](/filings/0001213900-25-108600.md) | [7.4](/filings/0001213900-26-088013.md) | [11.3](/filings/0001213900-26-088013.md) | [16.4](/filings/0001213900-26-088013.md) | [37.5](/filings/0001213900-25-108600.md) | [30.2](/filings/0001213900-26-088013.md) | [37.7](/filings/0001213900-26-088013.md) | [53.3](/filings/0001213900-26-088013.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,422) d](/filings/0001213900-24-097118.md) | [(4,439) d](/filings/0001213900-25-025828.md) | [(6,456)](/filings/0001213900-25-042943.md) | [(6,319) d](/filings/0001213900-25-076007.md) | [(9,252) d](/filings/0001213900-25-108600.md) | [(6,548) d](/filings/0001213900-26-035903.md) | [(8,903)](/filings/0001213900-26-054708.md) | [(8,420) d](/filings/0001213900-26-088013.md) | [(5,962) d](/filings/0001213900-25-108600.md) | [(8,032) d](/filings/0001213900-26-035903.md) | [(6,241)](/filings/0001213900-26-054708.md) | [(7,604) d](/filings/0001213900-26-088013.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001213900-24-097118.md) | [0.0 d](/filings/0001213900-25-025828.md) | [6.0](/filings/0001213900-25-042943.md) | [20.0 d](/filings/0001213900-25-076007.md) | [24.0 d](/filings/0001213900-25-108600.md) | [22.0 d](/filings/0001213900-26-035903.md) | [16.0](/filings/0001213900-26-054708.md) | [6.0 d](/filings/0001213900-26-088013.md) | [2.0 d](/filings/0001213900-25-108600.md) | [0.0 d](/filings/0001213900-26-035903.md) | [8.0](/filings/0001213900-26-054708.md) | [(1.0) d](/filings/0001213900-26-088013.md) |
| Dividends paid | $k | [100 d](/filings/0001213900-23-086979.md) | [0.0 d](/filings/0001213900-24-027202.md) | not reported | not reported | [0.0 d](/filings/0001213900-25-108600.md) | [0.0 d](/filings/0001213900-26-035903.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [15.1](/filings/0001213900-23-086979.md) | [15.2](/filings/0001213900-24-042298.md) | [15.2](/filings/0001213900-24-068565.md) | [32.6](/filings/0001213900-24-097118.md) | [34.9](/filings/0001213900-25-042943.md) | [9.4](/filings/0001213900-25-076007.md) | [8.9](/filings/0001213900-25-108600.md) | [12.4](/filings/0001213900-26-054708.md) | [12.3](/filings/0001213900-26-088013.md) | [18.1](/filings/0001213900-25-108600.md) | [23.9](/filings/0001213900-26-054708.md) | [26.9](/filings/0001213900-26-088013.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 27,855,257 at 2026-08-12, from the cover of the [10-Q filed 2026-08-12](/filings/0001213900-26-088013.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.